CTCL
Lymphir Approved for Adults With Relapsed or Refractory Cutaneous T-Cell Lymphoma
The FDA has approved denileukin diftitox-cxdl (Lymphir, Citius) for the treatment of relapsed or refractory (R/R) ...
AUGUST 9, 2024
Brentuximab Vedotin Beats Standard of Care for CTCL
The CD30-targeted antibody–drug conjugate brentuximab vedotin (BV) was far more active than current ...
MARCH 15, 2017
Load more